Akeso Reports Positive Results of Cadonilimab in P-III study for the treatment of Cervical Cancer
Shots:
- Akeso announces positive results from the P-III trial, evaluating cadonilimab + platinum-based CT +/- bevacizumab, for 1L treatment of recurrent/metastatic cervical cancer (R/M CC)
- The result of the 1EP, demonstrated a statistically significant and clinically meaningful PFS & OS evaluated by BICR based on RECIST v1.1 criteria during an interim analysis, inclusive of patients with different PD-L1 status, highlighting efficacy across diverse groups, additionally, the safety profile remains consistent
- Cadonilimab, a bispecific antibody targeting PD-1/CTLA-4, exhibits enhanced binding in tumor settings, minimal toxicities, and improved safety for effective anti-tumor therapy
Ref: PRNewswire | Image: Akeso
Related News:- Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
